{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:26:30Z","timestamp":1791206790600,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T00:00:00Z","timestamp":1424131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1038\/bjc.2014.638","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T20:56:15Z","timestamp":1424206575000},"page":"841-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma"],"prefix":"10.1038","volume":"112","author":[{"given":"T","family":"Scheller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hellerbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E K","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"issue":"3","key":"BFbjc2014638_CR1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2353\/ajpath.2010.090356","volume":"176","author":"T Amann","year":"2010","unstructured":"Amann T, Bataille F, Spruss T, Dettmer K, Wild P, Liedtke C, Muhlbauer M, Kiefer P, Oefner PJ, Trautwein C, Bosserhoff AK, Hellerbrand C (2010) Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol 176 (3): 1433\u20131442.","journal-title":"Am J Pathol"},{"issue":"4","key":"BFbjc2014638_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1349-7006.2009.01087.x","volume":"100","author":"T Amann","year":"2009","unstructured":"Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, Scholmerich J, Kiefer P, Bosserhoff AK, Hellerbrand C (2009) Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 100 (4): 646\u2013653.","journal-title":"Cancer Sci"},{"issue":"8","key":"BFbjc2014638_CR3","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/jcb.24135","volume":"113","author":"NS Azahri","year":"2012","unstructured":"Azahri NS, Di Bartolo BA, Khachigian LM, Kavurma MM (2012) Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration. J Cell Biochem 113 (8): 2597\u20132606.","journal-title":"J Cell Biochem"},{"issue":"3","key":"BFbjc2014638_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53 (3): 1020\u20131022.","journal-title":"Hepatology"},{"issue":"4","key":"BFbjc2014638_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (4): 299\u2013309.","journal-title":"Cancer Cell"},{"issue":"14","key":"BFbjc2014638_CR6","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/onc.2013.121","volume":"33","author":"A Casazza","year":"2013","unstructured":"Casazza A, Di Conza G, Wenes M, Finisguerra V, Deschoemaeker S, Mazzone M (2013) Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene 33 (14): 1743\u20131754.","journal-title":"Oncogene"},{"issue":"2","key":"BFbjc2014638_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bbrc.2012.12.006","volume":"430","author":"C Chen","year":"2013","unstructured":"Chen C, Cai SX, Wang GH, Cao XN, Yang X, Luo XL, Feng YD, Hu JB (2013) c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1 alpha. Biochem Biophys Res Commun 430 (2): 505\u2013511.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"BFbjc2014638_CR8","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3748\/wjg.v10.i10.1533","volume":"10","author":"J Cui","year":"2004","unstructured":"Cui J, Dong BW, Liang P, Yu XL, Yu DJ (2004) Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J Gastroenterol 10 (10): 1533\u20131536.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"BFbjc2014638_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/0008-5472.CAN-12-2064","volume":"73","author":"C Daly","year":"2013","unstructured":"Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, Thurston G (2013) Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73 (1): 108\u2013118.","journal-title":"Cancer Res"},{"issue":"3","key":"BFbjc2014638_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","volume":"3","author":"MV Dieci","year":"2013","unstructured":"Dieci MV, Arnedos M, Andre F, Soria JC (2013) Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 3 (3): 264\u2013279.","journal-title":"Cancer Discov"},{"issue":"7","key":"BFbjc2014638_CR11","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/1078-0432.CCR-11-1991","volume":"18","author":"RS Finn","year":"2012","unstructured":"Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW (2012) Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18 (7): 2090\u20132098.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"BFbjc2014638_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/hep.24099","volume":"53","author":"C Gauglhofer","year":"2011","unstructured":"Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stattner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B (2011) Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 53 (3): 854\u2013864.","journal-title":"Hepatology"},{"issue":"20","key":"BFbjc2014638_CR13","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1021\/jm2006222","volume":"54","author":"V Guagnano","year":"2011","unstructured":"Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H, Wartmann M, Berghausen J, Drueckes P, Zimmerlin A, Bussiere D, Murray J, Graus Porta D (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 54 (20): 7066\u20137083.","journal-title":"J Med Chem"},{"issue":"5-6","key":"BFbjc2014638_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000320463","volume":"78","author":"N Harimoto","year":"2010","unstructured":"Harimoto N, Taguchi K, Shirabe K, Adachi E, Sakaguchi Y, Toh Y, Okamura T, Kayashima H, Taketomi A, Maehara Y (2010) The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma. Oncology 78 (5-6): 361\u2013368.","journal-title":"Oncology"},{"issue":"3","key":"BFbjc2014638_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.gastro.2013.01.002","volume":"144","author":"V Hernandez-Gea","year":"2013","unstructured":"Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM (2013) Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144 (3): 512\u2013527.","journal-title":"Gastroenterology"},{"issue":"6","key":"BFbjc2014638_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.cellsig.2013.03.011","volume":"25","author":"CT Hu","year":"2013","unstructured":"Hu CT, Cheng CC, Pan SM, Wu JR, Wu WS (2013) PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2. Cell Signal 25 (6): 1457\u20131467.","journal-title":"Cell Signal"},{"issue":"7","key":"BFbjc2014638_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1582-4934.2008.00364.x","volume":"13","author":"H Huynh","year":"2009","unstructured":"Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, Poon D, Ngo VC, Tran E (2009) RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 13 (7): 1371\u20131380.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"BFbjc2014638_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61 (2): 69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"BFbjc2014638_CR19","doi-asserted-by":"publisher","first-page":"G464","DOI":"10.1152\/ajpgi.00078.2011","volume":"301","author":"GJ Kastanis","year":"2011","unstructured":"Kastanis GJ, Hernandez-Nazara Z, Nieto N, Rincon-Sanchez AR, Popratiloff A, Dominguez-Rosales JA, Lechuga CG, Rojkind M (2011) The role of dystroglycan in PDGF-BB-dependent migration of activated hepatic stellate cells\/myofibroblasts. Am J Physiol Gastrointest Liver Physiol 301 (3): G464\u2013G474.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"8","key":"BFbjc2014638_CR20","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/ijc.22442","volume":"120","author":"SA Lang","year":"2007","unstructured":"Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120 (8): 1803\u20131810.","journal-title":"Int J Cancer"},{"issue":"4","key":"BFbjc2014638_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.bbamcr.2010.01.009","volume":"1803","author":"SA Lang","year":"2010","unstructured":"Lang SA, Hackl C, Moser C, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O (2010) Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochim Biophys Acta 1803 (4): 435\u2013442.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"BFbjc2014638_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/hep.22685","volume":"49","author":"SA Lang","year":"2009","unstructured":"Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O (2009) Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49 (2): 523\u2013532.","journal-title":"Hepatology"},{"issue":"19","key":"BFbjc2014638_CR23","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","volume":"17","author":"C Lieu","year":"2011","unstructured":"Lieu C, Heymach J, Overman M, Tran H, Kopetz S (2011) Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 17 (19): 6130\u20136139.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014638_CR24","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61409-3","volume":"56","author":"JM Llovet","year":"2012","unstructured":"Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn R, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2012) Brivanib Versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the Phase 3 Brisk-PS Study. J Hepatol 56: S549\u2013S549.","journal-title":"J Hepatol"},{"issue":"4","key":"BFbjc2014638_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (4): 378\u2013390.","journal-title":"N Engl J Med"},{"issue":"4","key":"BFbjc2014638_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","volume":"60","author":"MS Matter","year":"2013","unstructured":"Matter MS, Decaens T, Andersen JB, Thorgeirsson SS (2013) Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 60 (4): 855\u2013865.","journal-title":"J Hepatol"},{"issue":"6","key":"BFbjc2014638_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1245\/s10434-007-9366-z","volume":"14","author":"RT Poon","year":"2007","unstructured":"Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14 (6): 1835\u20131845.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"BFbjc2014638_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0002-9610(01)00708-5","volume":"182","author":"RT Poon","year":"2001","unstructured":"Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J (2001) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182 (3): 298\u2013304.","journal-title":"Am J Surg"},{"issue":"5712","key":"BFbjc2014638_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science 307 (5712): 1098\u20131101.","journal-title":"Science"},{"issue":"11","key":"BFbjc2014638_CR30","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-11-0312","volume":"10","author":"J Taeger","year":"2011","unstructured":"Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA (2011) Targeting FGFR\/PDGFR\/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 10 (11): 2157\u20132167.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"BFbjc2014638_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2353\/ajpath.2007.060929","volume":"170","author":"JE Talmadge","year":"2007","unstructured":"Talmadge JE, Singh RK, Fidler IJ, Raz A (2007) Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170 (3): 793\u2013804.","journal-title":"Am J Pathol"},{"issue":"13","key":"BFbjc2014638_CR32","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26 (13): 1932\u20131940.","journal-title":"Oncogene"},{"issue":"1","key":"BFbjc2014638_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1756-9966-32-51","volume":"32","author":"YH Wang","year":"2013","unstructured":"Wang YH, Dong YY, Wang WM, Xie XY, Wang ZM, Chen RX, Chen J, Gao DM, Cui JF, Ren ZG (2013) Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-kappaB pathways induced by paracrine cytokines. J Exp Clin Cancer Res 32 (1): 51.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"BFbjc2014638_CR34","first-page":"220","volume":"4","author":"DF Yao","year":"2005","unstructured":"Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, Wu W, Qiu LW, Meng XY (2005) Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 4 (2): 220\u2013226.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"BFbjc2014638_CR35","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1172\/JCI66369","volume":"123","author":"C Yin","year":"2013","unstructured":"Yin C, Evason KJ, Asahina K, Stainier DY (2013) Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest 123 (5): 1902\u20131910.","journal-title":"J Clin Invest"},{"issue":"5","key":"BFbjc2014638_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","volume":"8","author":"AX Zhu","year":"2011","unstructured":"Zhu AX, Duda DG, Sahani DV, Jain RK (2011) HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 8 (5): 292\u2013301.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014638","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:27:00Z","timestamp":1684416420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,17]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["BFbjc2014638"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.638","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,17]]},"assertion":[{"value":"21 November 2014","order":1,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}